Source link : https://www.newshealth.biz/health-news/study-avoid-completion-alnd-for-abemaciclib-eligibility-in-early-breast-cancer/
The use of completion axillary lymph node dissection (cALND) to determine the need for adjuvant abemaciclib (Verzenio) among women with luminal estrogen receptor (ER)-positive, HER2-negative early breast cancer should be discouraged, according to a post-hoc analysis of the phase III SENOMAC trial. The prognostic procedure would need to be performed in 104 patients in order […]
Author : News Health
Publish date : 2024-08-09 20:10:47
Copyright for syndicated content belongs to the linked Source.
Categories